Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 177.50
Bid: 170.00
Ask: 185.00
Change: -2.50 (-1.39%)
Spread: 15.00 (8.824%)
Open: 180.00
High: 182.50
Low: 177.50
Prev. Close: 180.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

Thu, 13th Sep 2018 10:49

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank of Scotland, up 1.5%. The state-backed lender could use up to GBP4 billion of extra capital to pay out a special dividends to shareholders, The Times newspaper reported. RBS Chairman Howard Davies told the newspaper that, despite wanting to use the spare cash to buy the bank's shares from the government, if shareholders wanted the special dividend it was a possible option. The special dividend could be up to 33 pence per share to investors, who have not received a payout from the bank in more than 10 years, the newspaper reported. "If there are a lot of shareholders pressing for a special dividend, that is something we would consider," Davies told the Times. ----------Antofagasta, up 0.9%. HSBC raised the Chilean copper miner to Hold from Reduce. ----------FTSE 100 - LOSERS----------Marks & Spencer Group, down 2.7%. Shares in the food, clothing and homewares retailer were lower after department store chain John Lewis Partnership issued a warning for the full-year, amid "challenging times in retail". For the six months to July 28, John Lewis Partnership, which also owns the Waitrose supermarket chain, reported 81% drop in pretax profit to GBP6.0 million from GBP30.8 million a year before. On an adjusted basis, pretax profit slumped 99% to GBP1.2 million. At the end of June, the company had said it expected its interim profit to be "near zero". Looking ahead, John Lewis said that it continues to expect full-year profits to "be substantially lower than last year for the group as a whole". "John Lewis is the bellwether of the UK retail sector, so the fact it's finding life so hard is an indication of just how dire things are on the high street right now," said Hargreaves Lansdown analyst Laith Khalaf. Rival chain Debenhams was down 11%. ----------FTSE 250 - WINNERS----------Grainger, up 5.3%. The residential landlord was raised to Buy from Add by Numis. ----------KAZ Minerals, up 1.8%. HSBC upgraded the Kazakhstan-based miner to Buy from Hold. ----------FTSE 250 - LOSERS----------Inmarsat, down 2.0%, Equiniti Group, down 1.8%. The stocks went ex-dividend meaning new buyers no longer qualify for the latest dividend payout. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Bushveld Minerals, up 18%. The miner said it has raised its interest in the Vametco vanadium mine located near Pretoria, South Africa, to 75% from 59.1%. Bushveld has acquired the entire 21.22% interest that Sojitz Noble Alloys Corp held in Strategic Minerals Corp, the 75% owner of Vametco, for USD20 million in cash. Following completion of the deal, Bushveld via its Bushveld Vametco unit will own 100% of Strategic Minerals Corp and therefore have an indirect beneficial interest of 75% in the Vametco mine. The company used its existing cash resources to complete the stake acquisition.----------OTHER MAIN MARKET AND AIM - LOSERS----------Faron Pharmaceuticals, down 15%. The biopharmaceutical company said its loss for the first half of its financial year increased on higher research costs. For the six months to June 30, the firm posted pretax loss of EUR14.1 million compared to EUR7.1 million a year prior on increased research & development costs by 95% year-on-year to EUR11.7 million from EUR6.0 million. Administrative expenses also increased to EUR2.4 million from EUR1.5 million. As the company focuses on developing drugs, it only generated revenue of EUR20,000 from product sales to Maruishi Pharmaceutical. A year ago revenue was nil. Research expenses increased as a result of clinical costs associated with an unsuccessful trial of Traumakine, a treatment for acute respiratory distress syndrome, as well as an increase in development activities for Clevegen, a potential treatment for various types of cancer, the company explained.----------
More News
26 Aug 2021 14:56

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

Read more
25 Aug 2021 11:43

Faron doses first patient in Covid-19 treatment trial

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.

Read more
25 Aug 2021 11:38

IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment

IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment

Read more
19 Aug 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jun 2021 10:33

Faron Pharmaceuticals granted US patent for cancer immunotherapy drug

Faron Pharmaceuticals granted US patent for cancer immunotherapy drug

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 14:47

New research supports mode of action in Faron's 'MATINS' study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the publication of research supporting the immunotherapeutic blockade of 'Clever-1' to activate anti-tumour immune responses in advanced cancer patients on Thursday.

Read more
17 May 2021 17:49

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

Read more
17 May 2021 10:13

Faron Pharmaceuticals reports 'promising' data from drug study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced "promising" new data from its ongoing bexmarilimab 'MATINS' study on Monday, reporting combined headline data from 141 evaluable patients enrolled in the completed first part and the ongoing second part of the study.

Read more
14 May 2021 12:29

Faron Pharmaceuticals gets US rights to patent related to Traumakine

Faron Pharmaceuticals gets US rights to patent related to Traumakine

Read more
14 May 2021 11:18

Faron Pharmaceuticals signs US sublicence agreement

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has signed a sublicence agreement for the rights to United States patent US9,376,478, it announced on Friday, which currently extends to 2033.

Read more
23 Apr 2021 15:43

EXECUTIVE CHANGES: Universe Group hires CFO as new CEO also joins

EXECUTIVE CHANGES: Universe Group hires CFO as new CEO also joins

Read more
16 Apr 2021 14:54

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
25 Mar 2021 14:49

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

Read more
22 Mar 2021 11:22

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.